PAHC logo

PAHC

Research Snapshot

Static fundamentals, valuation context, and investor signals for Phibro Animal Health Corporation (PAHC).

DCF ready

Valuation

N/A

EV/FCF, N/A FCF yield

Quality

16.9%

ROIC, 3.2% FCF margin

Growth

10.1%

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 2.8x current ratio

Superinvestors

1

Top: Polen Capital Management (0.0%)

Strengths to research

  • Revenue compounded at 10.1% over five years.
  • Free cash flow compounded at 10.6% over five years.
  • ROIC is strong at 16.9%.
  • Debt/equity looks manageable at 0.0x.

Watchouts

  • Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for PAHC.

Grade C
52
/ 100

Financial Charts

No financial data available for PAHC (annual).

1 superinvestors own PAHC

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership
FundSharesValue% PortfolioQoQ Change
Polen Capital Management

Polen Capital Management

6,775$375,0000.00%0.0%